Why the study?
Does the BlueStar digital health tool reduce healthcare costs by improving A1C in patients with diabetes?
Does the BlueStar digital health tool reduce healthcare costs by improving A1C in patients with diabetes?
An economic analysis using MarketScan data demonstrated that A1C reductions associated with a digital health intervention (BlueStar) translate to significant healthcare cost savings.
Answers are grounded in this paper and cite their sources.
Economic valuation of diabetes outcomes supports digital tool assessment; leaves open real-world ROI translation.
The healthcare industry has had limited success in translating the value of innovative diabetes interventions into true economic return on investment. Our objective was to determine the value of improving diabetes outcomes and then to apply those values to the utilization of a digital health tool, BlueStar™. The analysis was conducted using the MarketScan® Research Databases owned by Truven Health Analytics®, part of IBM Watson Health™. These research data sets fully integrate de-identified patient-level health data, productivity, laboratory results, health risk assessments, hospital discharges, electronic medical records (EMR) and morbidity data into data available for research. Data are contributed by large employers, managed care organizations, hospitals, EMR providers, and Medicare and Medicaid programs. A complex algorithm was applied to the MarketScan data, resulting in quantified total costs broken down by A1C. We examined two population segments: commercial (age 40-64, n=2,320) and Medicare (age 65+, n=821). Cost estimates could thus directly be applied from the tables derived from the database to the A1C reductions associated with the BlueStar population of users, demonstrating significant cost savings associated with the use of BlueStar™.Healthcare Costs by A1C Band for Commercial and Medicare PopulationsCommercial PopulationMedicare PopulationA1C BandPercentage in BandAnnual Cost Per PatientPercentage in BandAnnual Cost Per Patient<7%30%$13,08042%$11,6537%-8%34%$14,29835%$13,7868%-9%16%$15,03614%$16,726>9%20%$19,9809%$17,036 Disclosure M. Shomali: Consultant; Self; WellDoc, Inc. A.K. Iyer: Employee; Self; WellDoc, Inc. B.T. Griffin: Other Relationship; Self; WellDoc, Inc. M. Peeples: Employee; Self; WellDoc, Inc..
No takes yet. Share an insight, caveat, or question.
Shomali et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: